[1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. DOI:
10.1177/1060028018797110[2] S D YOUNG. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase.[J]. Antimicrobial Agents and Chemotherapy, 1995, 39 12: 2602-2605. DOI:
10.1128/aac.39.12.2602[3] JAY A GROBLER. HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro.[J]. The Journal of Biological Chemistry, 2007, 282 11: 8005-8010. DOI:
10.1074/jbc.m608274200[4] CHRISTINE GOFFINET Oliver T K Ina Allespach. HIV-susceptible transgenic rats allow rapid preclinical testing of antiviral compounds targeting virus entry or reverse transcription.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2007: 1015-1020. DOI:
10.1073/pnas.0607414104[5] SHERAN M. The nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in the treatment of HIV.[J]. HIV Clinical Trials, 2005, 6 3: 158-168. DOI:
10.1310/4kc0-56tm-vlbf-78bn[6] NATELLA Y RAKHMANINA J N van den A. Efavirenz in the therapy of HIV infection.[J]. Expert Opinion on Drug Metabolism & Toxicology, 2010, 6 1: 95-103. DOI:
10.1517/17425250903483207
